Clinical efficacy of recombinant human thrombopoietin combined with glucocorticoids in the treatment of immune thrombocytopenia

References

• Qu M, Liu XN, Liu XG, et al. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. Cytokine. 2017;92:110–117.
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Eltonbary K, El Ghamry IR, et al. Intracranial hemorrhage in primary immune thrombocytopenia (ITP): 20 years’ experience in pediatrics. Eur J Pediatr 2021;180:1545–1552.
   PubMed Web of Science ®Google Scholar
• Kim HY, Park SW, Kim JH, et al. Romiplostim-related Myelofibrosis in Refractory Primary Immune Thrombocytopenia: A Case Report. Medicine (Baltimore). 2019;98:e15882.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang X, Li X, et al. Cost of bleeding-related episodes in adult patients With primary immune thrombocytopenia: A population-based retrospective cohort study of administrative claims data for commercial payers in the United States. Clin Ther. 2017;39:603–609.e1.
   PubMed Web of Science ®Google Scholar
• Yang ZG, Wen RT, Zhang YM, et al. Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating neuropilin-1 expression. Int Immunopharmacol 2019;72:437–444.
   PubMed Web of Science ®Google Scholar
• Xu Y, Pan Y, Zhou Z. Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model. J Thorac Dis. 2019;11:4671–4681.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang R, Han P, et al. Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model. Int Immunopharmacol 2019;67:287–293.
   PubMed Web of Science ®Google Scholar
• Liu WB, Li S, Yu XL, et al. Research progress on Chinese medicine immunomodulatory intervention for chronic primary immune thrombocytopenia: targeting cellular immunity. Chin J Integr Med. 2019;25:483–489.
   PubMed Web of Science ®Google Scholar
• Hemostasis and Thrombosis Group of the Chinese Medical Association Hematology Branch. Chinese expert consensus on the diagnosis and treatment of primary immune thrombocytopenia in adults (2016 edition). Chin J Hematol. 2016;37:89–93.
   Google Scholar
• Sun L, Wang J, Shao L, et al. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 2021;8:e289–e98.
   PubMed Web of Science ®Google Scholar
• Cui D, Lv Y, Yuan X, et al. Increased expressions of OX40 and OX40 ligand in patients with primary immune thrombocytopenia. J Immunol Res. 2019;2019:6804806.
   PubMed Web of Science ®Google Scholar
• Kado R, McCune WJ. Treatment of primary and secondary immune thrombocytopenia. Curr Opin Rheumatol. 2019;31:213–222.
   PubMed Web of Science ®Google Scholar
• Ptushkin VV, Vinogradova OY, Pankrashkina MM, et al. Thrombopoietin receptor agonists in the treatment of chronic resistant primary immune thrombocytopenia: efficacy and safety data in real. Clinical Practice Ter. Arkh. 2018;90:70–76.
   PubMed Web of Science ®Google Scholar
• Revilla N, Corral J, Miñano A, et al. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets. 2019;30:743–751.
   PubMed Web of Science ®Google Scholar
• Hernández-Sánchez JM, Bastida JM, Alonso-López D, et al. Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag. Platelets. 2020;31:993–1000.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang M, Hou Y, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. Am J Hematol 2020;95:1542–1552.
   PubMed Web of Science ®Google Scholar
• Sun HP, Hu Q, You JH, et al. Efficacy and safety of recombinant human thrombopoietin in adult patients with primary immune thrombocytopenia during the perioperative period. Zhonghua Xue Ye Xue Za Zhi. 2019;40:191–194.
   PubMedGoogle Scholar
• Luo HQ, Zhong YG, Feng WY. Effect of rhTPO on the immune function of T,B lymphocytes in patients with primary immune thrombocytopenic purpura. Chin J Exp Hematol. 2019;27:2089–2091.
   Google Scholar
• Cai HC, Wang SJ, Fu L, et al. A prospective study of the efficacy and safety of maintenance therapy with recombinant human thrombopoietin in patients with primary immune thrombocytopenia: a multicenter study. Zhonghua Xue Ye Xue Za Zhi. 2017;38:379–383.
   PubMedGoogle Scholar
• Sun H, Hu Q, You J, et al. Efficacy and safety of recombinant human thrombopoietin in adult patients with primary immune thrombocytopenia during the perioperative period. Zhonghua xue ye xue za zhi = Zhonghua Xueyexue Zazhi. 2019;40:191–194.
   PubMedGoogle Scholar
• Zhang YF, Zhou L, Yao GL, et al. Clinical trial of recombinant human thrombopoietin injection combined with dexamethasone injection and prednisone tablets in the treatment of severe immune thrombocytopenia. Chin J Clin Pharmacol. 2018;11:50–52.
   Google Scholar
• Zhou Z, Feng T, Xie Y, et al. The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis 2019;19:780.
   PubMed Web of Science ®Google Scholar
• Deng J, Hu H, Huang F, et al. Comparative efficacy and safety of thrombopoietin receptor agonists in adults With thrombocytopenia: A systematic review and network meta-analysis of randomized controlled trial front. Pharmacol. 2021;12:704093.
   Web of Science ®Google Scholar
• Zhang H, Pan X, Chen Z, et al. Changes in platelet surface CD41, CD62P and T lymphocyte subpopulation levels in patients with primary immune thrombocytopenia. Shandong Med J. 2014;54:60–62.
   Google Scholar
• Wu K, Zhao Y, Qu Z, et al. Efficacy of recombinant human thrombopoietin injection combined with hormone in the treatment of severe immune thrombocytopenia and the effect on T lymphocyte subsets in patients. Chin Pharm. 2019;22:1660–1662.
   Google Scholar